Though lifestyle modification has been proposed as a main stay for prevention and treatment of early type 2 diabetes, 2, 15-19 several new therapies for diabetes have been developed in recent years2. Incretins and incretin mimetics appear to hold promise. Oral DPP-4 inhibitors have been shown to increase EPCs in patients with type 2 diabetes 20 reportedly via SDF-1 alpha up-regulation. Interestingly, up-regulation of SDF-1 alpha and vascular endothelial growth factor (VEGF), both chemotactic factors increase mobilization and recruitment of EPCs in the face of acute ischemic injury for repair and regeneration.21-24.